Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talazoparib + enzalutamide
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Talazoparib + enzalutamide is a fixed combination therapy used to treat adults with metastatic castration-resistant prostate cancer (mCRPC) that has spread and harbors mutations in homologous recombination repair (HRR) genes. Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that blocks the PARP protein, impairing DNA repair in cancer cells and leading to cell death, particularly in tumors with defective DNA repair mechanisms. Enzalutamide is an androgen receptor antagonist that inhibits androgen receptor signaling, blocking hormones from fueling tumor growth even in castration-resistant settings. The combination was approved by the FDA based on improved radiographic progression-free survival and overall survival compared to enzalutamide alone[1][2][3][4][5].
- Brand names
- Talzenna + Xtandi
- Other names
- talazoparib + enzalutamide
02
Targets
AR (Adrenergic receptors)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on talazoparib + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talazoparib + enzalutamide.